Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

55.89USD
18 Jan 2019
Change (% chg)

$-0.32 (-0.57%)
Prev Close
$56.21
Open
$56.29
Day's High
$57.23
Day's Low
$54.94
Volume
450,924
Avg. Vol
211,457
52-wk High
$99.77
52-wk Low
$41.63

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $3,409.16
Shares Outstanding(Mil.): 48.39
Dividend: --
Yield (%): --

Financials

  AGIO.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -6.31 -- --
ROI: -46.41 8.99 14.48
ROE: -67.30 10.13 15.99

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

UPDATE 1-Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

Earnings vs. Estimates